Business Wire

Data Breaches Compromised 4.5 Billion Records in First Half of 2018

Share

Gemalto, the world leader in digital security, today released the latest findings of the Breach Level Index, a global database of public data breaches, revealing 945 data breaches led to 4.5 billion data records being compromised worldwide in the first half of 2018. Compared to the same period in 2017, the number of lost, stolen or compromised records increased by a staggering 133 percent, though the total number of breaches slightly decreased over the same period, signaling an increase in the severity of each incident.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181008005322/en/

Breach Level Index (Photo: Gemalto)

Breach Level Index (Photo: Gemalto)

A total of six social media breaches, including the Cambridge Analytica-Facebook incident, accounted for over 56 percent of total records compromised. Of the 945 data breaches, 189 (20 percent of all breaches) had an unknown or unaccounted number of compromised data records.

The Breach Level Index is a global database that tracks data breaches and measures their severity based on multiple dimensions, including the number of records compromised, the type of data, the source of the breach, how the data was used, and whether or not the data was encrypted. By assigning a severity score to each breach, the Breach Level Index provides a comparative list of breaches, distinguishing data breaches that are not serious versus those that are truly impactful.

According to the Breach Level Index, almost 15 billion data records have been exposed since 2013, when the index began benchmarking publicly disclosed data breaches. During the first six months of 2018, more than 25 million records were compromised or exposed every day, or 291 records every second, including medical, credit card and/or financial data or personally identifiable information. This is particularly concerning, since only one percent of the stolen, lost or compromised data records were protected by encryption to render the information useless, a percent-and-a-half drop compared to the first six months of 2017.

"Obviously, this year social media has been the top industry and threat vector for the compromise of personal data, a trend we can expect to continue with more and more sectors leveraging these platforms to reach key audiences, especially political teams gearing up for major elections," said Jason Hart, vice president and chief technology officer for data protection at Gemalto. "We also expect to see more data breaches reported by European Union countries bound by the new General Data Protection Regulation and in Australia with the new Notifiable Data Breaches law. We should be careful not to misconstrue this as an increase in overall incidents in these areas but rather as a more accurate reflection of what is actually going on."

Primary Sources of Data Breaches
Malicious outsiders caused the largest percentage of data breaches (56 percent), a slight decrease of almost seven percent over the second half of 2017 and accounted for over 80 percent of all stolen, compromised or lost records. Accidental loss accounted for over 879 million (9 percent) of the records lost this half, the second most popular cause of data breaches representing over one third of incidents. The number of records and incidents involved in malicious insider attacks fell by 50 percent this half compared to the same time period in 2017.

Leading Types of Data Breaches
Identity theft continues to be the leading type of data breach, as it has been since Gemalto first started tracking in 2013. While the number of identity theft breaches increased by 13 percent over the second half of 2017 to just over 64 percent, the number of records stolen through these incidents increased by 539 percent, representing over 87 percent of all records stolen.

Financial access incidents show a disturbing trend in the escalation of severity. Though overall incident numbers are on the decline H1 2017 vs. H1 2018 (171 for H1 2017 and 123 for H1 2018), the number of records breached increased H1 2017 vs. H1 2018 (2.7 million and 359million) respectively.

Industries Most Affected by Data Breaches
Most sectors saw an increase in the number of incidents compared to the previous half – the exceptions were government, professional services, retail and technology, though both government and retail saw an increase in the number of records breached through fewer events.

Healthcare continues to lead in number of incidents (27 percent). The largest such incident, 211 LA County, exposed 3.5 million records through accidental loss.

Social media ranks top for number of records breached (56 percent) due to the high-profile customer data compromises at Facebook and Twitter, involving 2.2 billion and 336 million respectively.

Geographic Distribution of Data Breaches
North America still makes up the majority of all breaches and the number of compromised records, 59 and 72 percent respectively. The United States is still by far and away the most popular target for attacks, representing more than 57 percent of global breaches and accounting for 72 percent of all records stolen, though overall incidents are down 17 percent over the prior half.

With the implementation of the Notifiable Data Breaches law, the number of incidents in Australia increased dramatically from 18 to 308 as could be expected.

Europe saw 36 percent fewer incidents but a 28 percent increase in the number of records breached indicating growing severity of attacks. The United Kingdom remains the most breached country in the region. With the General Data Protection Regulation in full effect for the second half of 2018, the number of reported incidents could begin to rise.

Related Resources:

  • For a full summary of data breach incidents by industry, source, type and geographic region, download the First Half 2017 Breach Level Index Report
  • Download the infographic here
  • Visit the BLI website here

About Gemalto

Gemalto (Euronext NL0000400653 GTO) is the global leader in digital security, with 2017 annual revenues of €3 billion and customers in over 180 countries. We bring trust to an increasingly connected world.

From secure software to biometrics and encryption, our technologies and services enable businesses and governments to authenticate identities and protect data so they stay safe and enable services in personal devices, connected objects, the cloud and in between.

Gemalto’s solutions are at the heart of modern life, from payment to enterprise security and the internet of things. We authenticate people, transactions and objects, encrypt data and create value for software – enabling our clients to deliver secure digital services for billions of individuals and things.

Our 15,000 employees operate out of 114 offices, 40 personalization and data centers, and 35 research and software development centers located in 47 countries.

For more information visit www.gemalto.com, or follow @gemalto on Twitter.

Contact information

Gemalto media contacts:
Tauri Cox
North America
+1 512 257 3916
tauri.cox@gemalto.com
or
Sophie Dombres
Europe Middle East & Africa
+33 4 42 36 57 38
sophie.dombres@gemalto.com
or
Piyush Prakash
Asia Pacific
+91 11 6623 1200
piyush.prakash@gemalto.com
or
Enriqueta Sedano
Latin America
+52 5521221422
enriqueta.sedano@gemalto.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New data show first-line triplet regimen of pembrolizumab, Herzuma ® (biosimilar trastuzumab) and chemotherapy are effective in treatment of HER2-positive advanced gastric cancer29.5.2020 01:01:00 CESTPress release

Data presented today as part of the ASCO20 Virtual Scientific Program show that a first-line triplet regimen comprising of pembrolizumab, Herzuma®(biosimilar trastuzumab) and chemotherapy is effective in patients with HER2-positive advanced gastric cancer (AGC). The PANTHERA trial (a phase Ib/II study of first line pembrolizumab in combination with trastuzumab, capecitabine, and cisplatin in HER2-positive gastric cancer), sponsored by Celltrion Inc. and MSD, is investigating the potential of a first-line immunotherapy/chemotherapy combination with biosimilar trastuzumab. This is in light of a growing body of evidence that the immune system contributes to the therapeutic effects of monoclonal antibodies such as biosimilar trastuzumab in treating solid tumours.1 A total of 43 patients were treated with a median follow up of 18 months. Patients were treated with pembrolizumab 200mg via IV infusion D1,biosimilar trastuzumab 6mg/kg (after 8mg/kg load) D1, capecitabine 1000mg/m2 bid D1-D14 a

European Commission Releases Takeda From Commitment to Divest Shire’s Pipeline Compound SHP64729.5.2020 01:00:00 CESTPress release

Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announces that on May 28, the European Commission (the “EC”) has released Takeda from the obligation to divest the pipeline compound SHP647 and certain associated rights (“SHP647”), a commitment that was provided by Takeda to secure regulatory clearance of its acquisition of Shire plc (“Shire”). Takeda will discontinue the current SHP647 clinical trial program, and it will be providing all eligible trial participants with the opportunity to have continued access to SHP647 in a post-trial access (“PTA”) study. In addition, subject to obtaining trial participant consents and the satisfaction of regulatory and ethical considerations, Takeda will make SHP647 clinical trial data and biosamples available to the scientific community through the Crohn’s & Colitis Foundation (“Foundation”). Takeda announced on November 20, 2018, that the EC approved its proposed acquisition of Shire (the “Acquisition”). The EC’s appr

Jefferies' Clients, Employees and Shareholders Contribute $9,250,000 to Over 85 Charities for Coronavirus Relief in Memory of Peg Broadbent28.5.2020 18:02:00 CESTPress release

Jefferies announced today a total donation to over 85 different charities of $9.25 million as a result of a firmwide global effort to raise money to honor the memory of their late CFO Peg Broadbent, who was a victim of this terrible disease. Through the firm’s Global Coronavirus Relief Charity Day held May 27th, Jefferies’ clients helped to generate $7.65 million in donated net trading commissions. In addition, Jefferies as a firm will donate $1 million directly, and voluntary donations from Jefferies’ 3,822 employees totaled $600,000. “We could not be prouder of our entire Jefferies family for raising $9.25 million and are greatly appreciative of the incredible partnership our clients have shown us in supporting our fight against Covid-19. The full $9.25 million will be wired today and go to direct relief efforts at over 85 worthy global charities who are each in the front lines helping those most impacted by the Coronavirus global pandemic. We went broadly to a large number of charit

JRJ Group Announces Sale of ETX Capital to Guru Capital28.5.2020 15:30:00 CESTPress release

JRJ Group, a leading international private equity investment firm focused on the financial services sector and growth situations, is pleased to announce that it has agreed to terms for the sale of ETX Capital, one of the fastest growing international providers of multi-asset CFDs and spread betting products, to a fund associated with Guru Capital, a Switzerland-based private equity firm with specific experience in the CFD space. Terms of the transaction were not disclosed. Roger Nagioff, Founding Partner of JRJ Group, said, “During JRJ’s ownership, we have invested in bolt-on acquisitions and enhanced the technology of the firm. We are delighted with the strength and resilience of the platform we have built, alongside the management team and employees, and we wish the enterprise every success in its next stage of growth.” “We are grateful of JRJ Group’s support, and we look forward to growing the business with the Guru Capital team, who have substantial experience in the CFD sector,” s

eLichens Launches eStore for US and EU Markets28.5.2020 15:00:00 CESTPress release

French start-up eLichens has launched its online store last week. eLos, for eLichens Outdoor Station, can now be purchased online by US and EU customers. Japan and other areas will soon join the list. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200528005117/en/ (Photo: Business Wire) eLos is a wireless, solar-powered air quality station. eLos provides citizens, communities and organizations the most accurate and complete real-time data about air quality, wherever they need it. Visit the store and learn more about eLos : https://www.elichens.com/store/elos View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005117/en/Contact information Marc Attia, press@elichens.com

SAB Biotherapeutics Confirms Neutralizing Antibodies to SARS-CoV-2 and Begins Clinical Manufacturing of Novel COVID-19 Therapeutic Candidate28.5.2020 14:24:00 CESTPress release

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors, today announced in vitro data demonstrating that SAB-185, its COVID-19 therapeutic candidate, has highly-potent neutralizing antibodies to SARS-CoV-2 that are four times higher than the most potent human convalescent plasma serum sample evaluated. The company also announced that they initiated manufacturing of SAB-185 on May 25 to support the next phase of clinical development for its potential COVID-19 therapeutic, still on track to begin human trials in early summer. “These data indicate this human polyclonal antibody therapeutic has potent neutralizing activity against live SARS-CoV-2. The neutralizing titers of SAB-185 are significantly higher than those of the most potent plasma of recovered COVID-19 patients we’ve been able to source,” said William B. Klimstra, PhD Associate Professor of Microbio